Reference : Association between polymorphism in IgG Fc receptor IIIa coding gene and biological r...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/25408
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
English
Louis, Edouard mailto [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie >]
El Ghoul, Z. [> > > >]
Vermeire, S. [> > > >]
Dall'Ozzo, S. [> > > >]
Rutgeerts, P. [> > > >]
Paintaud, G. [> > > >]
Belaiche, Jacques [Université de Liège - ULg > Département des sciences cliniques > Hépato-gastroentérologie]
De Vos, M. [> > > >]
Van Gossum, A. [> > > >]
Colombel, J. F. [> > > >]
Watier, H. [> > > >]
1-Mar-2004
Alimentary Pharmacology & Therapeutics
Blackwell Publishing Ltd
19
5
511-519
Yes (verified by ORBi)
International
0269-2813
Oxford
[en] AIM: To test the hypothesis of an association between polymorphism in FCGR3A (the gene coding for FcgammaRIIIa, which is expressed on macrophages and natural killer cells, is involved in antibody-dependent cell-mediated cytotoxicity and has recently been associated with a positive response to rituximab, a recombinant immunoglobulin G1 antibody used in non-Hodgkin's lymphomas) and response to infliximab in Crohn's disease. METHODS: FCGR3A-158 polymorphism was determined using an allele-specific polymerase chain reaction assay in 200 Crohn's disease patients who had received infliximab for either refractory luminal (n = 142) or fistulizing (n = 58) Crohn's disease. Clinical and biological responses (according to C-reactive protein levels) were assessed in 200 and 145 patients, respectively. RESULTS: There were 82.9% clinical responders in V/V patients vs. 72.7% in V/F and F/F patients (N.S.). Globally, the decrease in C-reactive protein was significantly higher in V/V patients than in F carriers (P = 0.0078). A biological response was observed in 100% of V/V patients, compared with 69.8% of F carriers (P = 0.0002; relative risk, 1.43; 95% confidence interval, 1.27-1.61). In the sub-group of patients with elevated C-reactive protein before treatment, the multivariate analysis selected the use of immunosuppressive drugs and FCGR3A genotype as independent factors influencing the clinical response to infliximab (P = 0.003). CONCLUSION: Crohn's disease patients with FCGR3A-158 V/V genotype have a better biological and, possibly, clinical response to infliximab.
http://hdl.handle.net/2268/25408

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Postp Aut-Association between polymorphism in... 2004 traité OCR.pdfAuthor postprint243.31 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.